OmniAb Inc

NASDAQ:OABIUnited States

OmniAb, Inc. offers a discovery platform that provides pharmaceutical industry partners with access to diverse antibody repertoires and high-throughput screening technologies to enable the discovery of next-generation therapeutics. The OmniAb platform is the biological intelligence (BI) of transgenic animals, including OmniRat, OmniChicken, and OmniMouse, which have been genetically modified to generate antibodies with human sequences to facilitate the development of human therapeutic candidates. The Company’s OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications through a common light chain approach, and OmniTaur features structural attributes of cow antibodies for complex targets. The Company's OmniChicken and OmniClic offer affinity-matured antibodies in an evolutionarily distant chicken host environment, which can deliver a diverse repertoire of antibody panels to conserved therapeutic target antigens.

Contact Information

Headquarters

5980 Horton Street, Suite 600EMERYVILLE, CA, United States 94608

Phone

510-250-7800

Fax

302-636-5454

Executives

Chairman of the Board

John Higgins

President, Chief Executive Officer, Director

Matthew Foehr

Chief Financial Officer, Executive Vice President - Finance

Kurt Gustafson

Chief Legal Officer, Secretary

Charles Berkman

Independent Director

Carolyn Bertozzi